HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME Test (opens in a new window) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gandhi, S. N. Articles by Sirlin, C. B. Search for Related Content PubMed PubMed Citation Articles by Gandhi, S. N. Articles by Sirlin, C. B. Related Collections Gastrointestinal Radiology Magnetic Resonance Imaging

MR Contrast Agents for Liver Imaging: What, When, How¹

¹ From the Department of Radiology, UCSD Medical Center, 200 W Arbor Dr, San Diego, CA 92103. Recipient of a Certificate of Merit award for an education exhibit at the 2004 RSNA Annual Meeting. Received February 6, 2006; revision requested March 16 and received May 5; accepted May 8. All authors have no financial relationships to disclose. Address correspondence to C.B.S. (e-mail: csirlin{at}ucsd.edu).

The major classes of contrast agents currently used for magnetic resonance (MR) imaging of the liver include extracellular agents (eg, low-molecular-weight gadolinium chelates), reticuloendothelial agents (eg, ferumoxides), hepatobiliary agents (eg, mangafodipir), blood pool agents, and combined agents. Mechanisms of action, dosage, elimination, toxic effects, indications for use, and MR imaging technical considerations vary according to class. Gadolinium chelates are the most widely used. Ferumoxides are a useful adjunct for detection of hepatocellular carcinoma, particularly when used in combination with gadolinium to achieve improved lesion-to-liver contrast over that achievable with gadolinium alone. Mangafodipir is a prototype hepatobiliary agent that is taken up by lesions with functioning hepatocytes. It may be used for MR cholangiography as well as liver imaging. Although mangafodipir is no longer commercially available in the United States, it is currently marketed and used in Europe. Blood pool agents have not yet been approved for human use in the United States. However, a new combined MR contrast agent, gadobenate dimeglumine, recently was approved, and other agents are in various stages of development.

© RSNA, 2006

This article has been cited by other articles:

				R. F. Hanna, D. A. Aguirre, N. Kased, S. C. Emery, M. R. Peterson, and C. B. Sirlin Cirrhosis-associated Hepatocellular Nodules: Correlation of Histopathologic and MR Imaging Features RadioGraphics, May 1, 2008; 28(3): 747 - 769. [Abstract] [Full Text] [PDF]

				A.G. Bleicher and E. Kanal A Serial Dilution Study of Gadolinium-Based MR Imaging Contrast Agents AJNR Am. J. Neuroradiol., April 1, 2008; 29(4): 668 - 673. [Abstract] [Full Text] [PDF]